The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Equine Rhinopneumonitis Vaccine Market Research Report 2024
Synopsis
Equine Rhinopneumonitis Vaccine can prevent Equine Rhinopneumonitis，viruses that are prevalent in horses and can cause outbreaks of respiratory disease.
The global Equine Rhinopneumonitis Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Equine Rhinopneumonitis Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Equine Rhinopneumonitis Vaccine.
Report Scope
The Equine Rhinopneumonitis Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Equine Rhinopneumonitis Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Equine Rhinopneumonitis Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Nisseiken Co., Ltd.
Boehringer Ingelheim
Santa Cruz Animal Health
Merck
Segment by Type
Live
Inactivated
Segment by Application
Veterinary Pharmacy
Online Sale
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Equine Rhinopneumonitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Equine Rhinopneumonitis Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Equine Rhinopneumonitis Vaccine can prevent Equine Rhinopneumonitis，viruses that are prevalent in horses and can cause outbreaks of respiratory disease.
The global Equine Rhinopneumonitis Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Equine Rhinopneumonitis Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Equine Rhinopneumonitis Vaccine.
Report Scope
The Equine Rhinopneumonitis Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Equine Rhinopneumonitis Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Equine Rhinopneumonitis Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Nisseiken Co., Ltd.
Boehringer Ingelheim
Santa Cruz Animal Health
Merck
Segment by Type
Live
Inactivated
Segment by Application
Veterinary Pharmacy
Online Sale
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Equine Rhinopneumonitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Equine Rhinopneumonitis Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Equine Rhinopneumonitis Vaccine Market Overview
1.1 Product Overview and Scope of Equine Rhinopneumonitis Vaccine
1.2 Equine Rhinopneumonitis Vaccine Segment by Type
1.2.1 Global Equine Rhinopneumonitis Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Live
1.2.3 Inactivated
1.3 Equine Rhinopneumonitis Vaccine Segment by Application
1.3.1 Global Equine Rhinopneumonitis Vaccine Market Value by Application: (2024-2030)
1.3.2 Veterinary Pharmacy
1.3.3 Online Sale
1.3.4 Others
1.4 Global Equine Rhinopneumonitis Vaccine Market Size Estimates and Forecasts
1.4.1 Global Equine Rhinopneumonitis Vaccine Revenue 2019-2030
1.4.2 Global Equine Rhinopneumonitis Vaccine Sales 2019-2030
1.4.3 Global Equine Rhinopneumonitis Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Equine Rhinopneumonitis Vaccine Market Competition by Manufacturers
2.1 Global Equine Rhinopneumonitis Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Equine Rhinopneumonitis Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Equine Rhinopneumonitis Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Equine Rhinopneumonitis Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Equine Rhinopneumonitis Vaccine, Product Type & Application
2.7 Equine Rhinopneumonitis Vaccine Market Competitive Situation and Trends
2.7.1 Equine Rhinopneumonitis Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Equine Rhinopneumonitis Vaccine Players Market Share by Revenue
2.7.3 Global Equine Rhinopneumonitis Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Equine Rhinopneumonitis Vaccine Retrospective Market Scenario by Region
3.1 Global Equine Rhinopneumonitis Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Equine Rhinopneumonitis Vaccine Global Equine Rhinopneumonitis Vaccine Sales by Region: 2019-2030
3.2.1 Global Equine Rhinopneumonitis Vaccine Sales by Region: 2019-2024
3.2.2 Global Equine Rhinopneumonitis Vaccine Sales by Region: 2025-2030
3.3 Global Equine Rhinopneumonitis Vaccine Global Equine Rhinopneumonitis Vaccine Revenue by Region: 2019-2030
3.3.1 Global Equine Rhinopneumonitis Vaccine Revenue by Region: 2019-2024
3.3.2 Global Equine Rhinopneumonitis Vaccine Revenue by Region: 2025-2030
3.4 North America Equine Rhinopneumonitis Vaccine Market Facts & Figures by Country
3.4.1 North America Equine Rhinopneumonitis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Equine Rhinopneumonitis Vaccine Sales by Country (2019-2030)
3.4.3 North America Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Equine Rhinopneumonitis Vaccine Market Facts & Figures by Country
3.5.1 Europe Equine Rhinopneumonitis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Equine Rhinopneumonitis Vaccine Sales by Country (2019-2030)
3.5.3 Europe Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Equine Rhinopneumonitis Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Equine Rhinopneumonitis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Equine Rhinopneumonitis Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Equine Rhinopneumonitis Vaccine Market Facts & Figures by Country
3.7.1 Latin America Equine Rhinopneumonitis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Equine Rhinopneumonitis Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Equine Rhinopneumonitis Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Equine Rhinopneumonitis Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Equine Rhinopneumonitis Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Equine Rhinopneumonitis Vaccine Sales by Type (2019-2030)
4.1.1 Global Equine Rhinopneumonitis Vaccine Sales by Type (2019-2024)
4.1.2 Global Equine Rhinopneumonitis Vaccine Sales by Type (2025-2030)
4.1.3 Global Equine Rhinopneumonitis Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Equine Rhinopneumonitis Vaccine Revenue by Type (2019-2030)
4.2.1 Global Equine Rhinopneumonitis Vaccine Revenue by Type (2019-2024)
4.2.2 Global Equine Rhinopneumonitis Vaccine Revenue by Type (2025-2030)
4.2.3 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Equine Rhinopneumonitis Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Equine Rhinopneumonitis Vaccine Sales by Application (2019-2030)
5.1.1 Global Equine Rhinopneumonitis Vaccine Sales by Application (2019-2024)
5.1.2 Global Equine Rhinopneumonitis Vaccine Sales by Application (2025-2030)
5.1.3 Global Equine Rhinopneumonitis Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Equine Rhinopneumonitis Vaccine Revenue by Application (2019-2030)
5.2.1 Global Equine Rhinopneumonitis Vaccine Revenue by Application (2019-2024)
5.2.2 Global Equine Rhinopneumonitis Vaccine Revenue by Application (2025-2030)
5.2.3 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Equine Rhinopneumonitis Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Corporation Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Equine Rhinopneumonitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Zoetis Equine Rhinopneumonitis Vaccine Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Nisseiken Co., Ltd.
6.2.1 Nisseiken Co., Ltd. Corporation Information
6.2.2 Nisseiken Co., Ltd. Description and Business Overview
6.2.3 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Product Portfolio
6.2.5 Nisseiken Co., Ltd. Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Santa Cruz Animal Health
6.4.1 Santa Cruz Animal Health Corporation Information
6.4.2 Santa Cruz Animal Health Description and Business Overview
6.4.3 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Product Portfolio
6.4.5 Santa Cruz Animal Health Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Equine Rhinopneumonitis Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck Equine Rhinopneumonitis Vaccine Product Portfolio
6.5.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Equine Rhinopneumonitis Vaccine Industry Chain Analysis
7.2 Equine Rhinopneumonitis Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Equine Rhinopneumonitis Vaccine Production Mode & Process
7.4 Equine Rhinopneumonitis Vaccine Sales and Marketing
7.4.1 Equine Rhinopneumonitis Vaccine Sales Channels
7.4.2 Equine Rhinopneumonitis Vaccine Distributors
7.5 Equine Rhinopneumonitis Vaccine Customers
8 Equine Rhinopneumonitis Vaccine Market Dynamics
8.1 Equine Rhinopneumonitis Vaccine Industry Trends
8.2 Equine Rhinopneumonitis Vaccine Market Drivers
8.3 Equine Rhinopneumonitis Vaccine Market Challenges
8.4 Equine Rhinopneumonitis Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Equine Rhinopneumonitis Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Equine Rhinopneumonitis Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Equine Rhinopneumonitis Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Equine Rhinopneumonitis Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Equine Rhinopneumonitis Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Equine Rhinopneumonitis Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Equine Rhinopneumonitis Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Equine Rhinopneumonitis Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Equine Rhinopneumonitis Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Equine Rhinopneumonitis Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Equine Rhinopneumonitis Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Equine Rhinopneumonitis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Equine Rhinopneumonitis Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Equine Rhinopneumonitis Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Equine Rhinopneumonitis Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Equine Rhinopneumonitis Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Equine Rhinopneumonitis Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Equine Rhinopneumonitis Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Equine Rhinopneumonitis Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Equine Rhinopneumonitis Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Equine Rhinopneumonitis Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Equine Rhinopneumonitis Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Equine Rhinopneumonitis Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Equine Rhinopneumonitis Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Equine Rhinopneumonitis Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Equine Rhinopneumonitis Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Equine Rhinopneumonitis Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Equine Rhinopneumonitis Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Equine Rhinopneumonitis Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Equine Rhinopneumonitis Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Equine Rhinopneumonitis Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Equine Rhinopneumonitis Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Equine Rhinopneumonitis Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Equine Rhinopneumonitis Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Equine Rhinopneumonitis Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Equine Rhinopneumonitis Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Equine Rhinopneumonitis Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Equine Rhinopneumonitis Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Equine Rhinopneumonitis Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Equine Rhinopneumonitis Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Equine Rhinopneumonitis Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Equine Rhinopneumonitis Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Equine Rhinopneumonitis Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Equine Rhinopneumonitis Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Equine Rhinopneumonitis Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Equine Rhinopneumonitis Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Equine Rhinopneumonitis Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Equine Rhinopneumonitis Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Equine Rhinopneumonitis Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Zoetis Corporation Information
Table 71. Zoetis Description and Business Overview
Table 72. Zoetis Equine Rhinopneumonitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Zoetis Equine Rhinopneumonitis Vaccine Product
Table 74. Zoetis Recent Developments/Updates
Table 75. Nisseiken Co., Ltd. Corporation Information
Table 76. Nisseiken Co., Ltd. Description and Business Overview
Table 77. Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Product
Table 79. Nisseiken Co., Ltd. Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Santa Cruz Animal Health Corporation Information
Table 86. Santa Cruz Animal Health Description and Business Overview
Table 87. Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Product
Table 89. Santa Cruz Animal Health Recent Developments/Updates
Table 90. Merck Corporation Information
Table 91. Merck Description and Business Overview
Table 92. Merck Equine Rhinopneumonitis Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck Equine Rhinopneumonitis Vaccine Product
Table 94. Merck Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Equine Rhinopneumonitis Vaccine Distributors List
Table 98. Equine Rhinopneumonitis Vaccine Customers List
Table 99. Equine Rhinopneumonitis Vaccine Market Trends
Table 100. Equine Rhinopneumonitis Vaccine Market Drivers
Table 101. Equine Rhinopneumonitis Vaccine Market Challenges
Table 102. Equine Rhinopneumonitis Vaccine Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Equine Rhinopneumonitis Vaccine
Figure 2. Global Equine Rhinopneumonitis Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Equine Rhinopneumonitis Vaccine Market Share by Type in 2023 & 2030
Figure 4. Live Product Picture
Figure 5. Inactivated Product Picture
Figure 6. Global Equine Rhinopneumonitis Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Equine Rhinopneumonitis Vaccine Market Share by Application in 2023 & 2030
Figure 8. Veterinary Pharmacy
Figure 9. Online Sale
Figure 10. Others
Figure 11. Global Equine Rhinopneumonitis Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Equine Rhinopneumonitis Vaccine Market Size (2019-2030) & (US$ Million)
Figure 13. Global Equine Rhinopneumonitis Vaccine Sales (2019-2030) & (K Units)
Figure 14. Global Equine Rhinopneumonitis Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 15. Equine Rhinopneumonitis Vaccine Report Years Considered
Figure 16. Equine Rhinopneumonitis Vaccine Sales Share by Manufacturers in 2023
Figure 17. Global Equine Rhinopneumonitis Vaccine Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Equine Rhinopneumonitis Vaccine Players: Market Share by Revenue in 2023
Figure 19. Equine Rhinopneumonitis Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Equine Rhinopneumonitis Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2019-2030)
Figure 22. North America Equine Rhinopneumonitis Vaccine Revenue Market Share by Country (2019-2030)
Figure 23. United States Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2019-2030)
Figure 26. Europe Equine Rhinopneumonitis Vaccine Revenue Market Share by Country (2019-2030)
Figure 27. Germany Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Equine Rhinopneumonitis Vaccine Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Equine Rhinopneumonitis Vaccine Revenue Market Share by Region (2019-2030)
Figure 34. China Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2019-2030)
Figure 44. Latin America Equine Rhinopneumonitis Vaccine Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Colombia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Equine Rhinopneumonitis Vaccine Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Equine Rhinopneumonitis Vaccine Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Equine Rhinopneumonitis Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Equine Rhinopneumonitis Vaccine by Type (2019-2030)
Figure 55. Global Revenue Market Share of Equine Rhinopneumonitis Vaccine by Type (2019-2030)
Figure 56. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Equine Rhinopneumonitis Vaccine by Application (2019-2030)
Figure 58. Global Revenue Market Share of Equine Rhinopneumonitis Vaccine by Application (2019-2030)
Figure 59. Global Equine Rhinopneumonitis Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 60. Equine Rhinopneumonitis Vaccine Value Chain
Figure 61. Equine Rhinopneumonitis Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
